Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04267393 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT04267393 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 124 participants.
The verdict
NCT04267393, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
Interventions
- OTHER Placebo
- DRUG BMS-986263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04267393
The ClinicalTrials.gov registry entry for NCT04267393 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04267393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04267393 about?
NCT04267393 is a clinical study titled "Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)". The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
What is the current status of trial NCT04267393?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2021-03-17. Estimated completion is 2024-02-09.
What interventions are being tested in trial NCT04267393?
The interventions under investigation include: Placebo (OTHER), BMS-986263 (DRUG).
Who is sponsoring clinical trial NCT04267393?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.